Overview
Valued at ~$779 million in 2023, the oncology embolization agents market is projected to reach
~$1.2 billion by 2028, increasing at a CAGR of 8.6% over the 2023-2028
forecast period. This Market Snapshot is part of LSI’s Market Intelligence platform, your
one-stop-shop for global medtech market sizing and analysis, procedure volume data, startup company- and
deal-tracking, curated insights, and more.
Embolization is a therapeutic modality that induces targeted occlusion of blood vessels to destroy tumors and
lesions, such as uterine fibroids, arteriovenous malformations (AVMs), and carcinomas. This technique utilizes
embolization agents delivered through a catheter during image-guided procedures. Some agents, such as Sirtex’s
SIR-SpheresⓇ, use radioactive materials, providing a dual therapeutic effect by exposing the tumor to localized
radiation while simultaneously cutting off its blood supply.
Products included within the scope of this analysis include:
Embolic microspheres
Transcatheter arterial chemoembolization agents
Liquid embolic agents
This Market Snapshot is intended to provide a high-level overview of the global market for oncology embolization
agents, with key insights into:
Unit volumes from 2023 to 2028
Market forecasts from 2023 to 2028
Market insights
Competitive landscape analysis of major competitors
Insights into key market events for strategic and startups
Oncology Embolization Agents Market Snapshot Summary
| Snapshot Aspect | Data and Details |
| Base Year for Estimate | 2023 |
| Forecast Period | 2023 - 2028 |
| Market Size in 2023 | $779 million |
| CAGR | 8.6% |
| Projected Market Size in 2028 | $1.2 billion |
Oncology Embolization Agents Market Insights
The oncology embolization agents market is poised for significant growth, driven by an increasing incidence of
various cancer types treated with embolization devices, including radioembolization, chemoembolization, and
particle embolization devices. The scope of this analysis also includes embolization devices used for uterine
fibroid embolization as well as for embolization of peripheral vascular malformations and internal hemorrhage.
Liver cancer remains the predominant indication for embolization, with its global incidence expected to rise at
an annual rate of 2.4% from 2022 to 2030. This uptick in liver cancer cases is anticipated to bolster demand for
embolization procedures.
A notable trend within the global market is the substantial increase in the adoption of radioembolization
therapy, particularly with the use of SIR-Sphere particles for liver cancer treatment. The number of
radioembolization procedures has surged approximately fourfold between 2012 and 2023, reflecting a growing
acceptance of this therapeutic approach.
Competitive Landscape
The full Market Snapshot includes a robust analysis of the competitive landscape for the oncology embolization
agents market. This includes estimated market revenue and market share for key players, such as Boston
Scientific, Sirtex Medical, and Merit Medical.
Select Market Events
| Company | Date | Event Type | Event |
|
Sirtex
|
3/2024 | New Hire | Sirtex Medical appointed Matt Schmidt as CEO and Board of Directors member. |
|
Merit Medical
|
10/2024 | Regulatory | Merit Medical announced the launch of its Siege™ Vascular Plug, which received U.S. 510(k) clearance earlier this year. |
Key Companies Covered
Arsenal Medical
Boston Scientific
Cook Medical
Cordis
Instylla
Medtronic
Merit Medical
Sirtex Medical
Stryker
Terumo
Varian
